Version 1.0.3

Submission Home > Submission

You can use the options below to view your submission. Where appropriate you can also add to and update your submission and send the details for approval.

Submission Details	
Status	Accepted
Open Date	01/10/2016
Deadline Date	31/10/2016
Date Submitted	24/10/2016
Type	Historic Performance in Initiating
NHS provider	Maidstone and Tunbridge Wells NHS Trust

Showing records 1 to 25 of 27. Pages: 1 2 Next >

88	88	Id
9614	9613	
₩EM/0172	3/NW/0501	Research Ethics Committee Reference Number
142310	123836	Integrated Research Application System Number
NHS Permission	HRA Approval	Submission Type
BABY OSCAR- Outcome after Selective early Treatment for Closure of patient Ductus Arteriosus in Pre-term babies.	QUAZAR CC-486- AMIL-001: A Phase 3, ramdomized, double-blind, placebo-controlled study to compare efficacy and safety of oral azacitidine plus best supportive care versus best supportive care supportive care supportive care supportive care supportive care wersus best supportive care as maintenance therapy in subjects with acute myeloid Leukemia in	Name of Trial
13/10/2015		Date of Receipt of Valid Research Application
		Date of First NHS Patient Permission Recruited?
N _O	N _O	First Patient Recruited?
4		Date of First Patient Recruited
22		Duration between VRA and NHS Permission
		Duration Dura between VRA NHS Permission and and First Patient Patie
		Duration between VRA VRA First Patient
	114	buration between Date Site Selected and Date Site Confirmed
		Santa
		desire.
N ₀		Benchmark Date Site Met Invited
	12/01/2016	
	12/01/2016 2	Date Site A
	5/04/2016 26	HRA C Approval B Date S
	V04/2016 05	Date Site Confirmed D: By C: Sponsor
Ple Sei	V05/2016	Date Site Confirmed
	BABY OSCAR- Outcome after Selective early Treatment for Closure of patient Ductus Arteriosus in Pre-term babies.	AML-001: A Phase 3. ramdomized, double-blind, placebo-controlled study to compane efficacy and safety of oral azacitidine plus best supportive care s supportive care s maintenance therapy in subjects with acute myeloid Leukemia in BABY OSCAR- Outcome after Closure of patient Ductus Arteriosus in Pre-term babies. 13/10/2015 12/02/2016 No 122

896	8961	8961	89616	2/5/2018
89619 13/EM/0348 122371	89618 14/YH/1056	89617 15/LO/1807	89616 15/WM/0457	2018 89615 15/EM/0473 187844
3 122371	147421	187302	195511	187844
NHS Permission	HRA Approval	NHS Permission	NHS Permission	HRA Approval
Monoprost compared with Lumigan in POA glaucoma/ocular hypertention	AB 10004 Study- A Multicenter, Randomised, Open-label, three-parallel groups, phase 2-3 study to evuate the effiency and safety of mastinib with dexamenthasone gemcitabine with dexamethasone and the combination of mastinib, gemcitabine and dexamethasone and the combination of gemcitabine and dexamethasone and the combination of gemcitabine and dexamethasone	Checkmate 331 An Open-label, Randomized, Phase 3 study of Nivolumab or chemotherapy in subjects with replases small-cell lung cancer after Platinum- Based first line chemotherapy. CA209-331	DARATUMUMAB: An Open-Labbel Treatment Use Protocol for Subjects with Mulitple Muyeloma Who Have Received at Least Who Have Received at Least O2/03/2016 Therapy (Including a Proteasome Inhibitor and an Immunomodulatory Agent) or are Double Refractory to a Proteas	anetumab raviansine (BAY 94-9343) or vinorelbine in patients with advanced or metastatic malignant pleural mesothelioma overexpressing mesothelin and progressin
26/10/2015		25/01/2016	02/03/2016	
30/10/2015		23/02/2016	10/03/2016	
	Yes	Yes	Yes	Z 0
	19/10/2016	20/07/2016 29	22/03/2016 8	CTP Submission Platform - Submission (Version 1.0.3)
4		29		ssion Platfo
		148	12	orm - Subm
		177	20	nission (Ve
	95			Version 1.0.3
	117			
	212	7	4	Z C
×	Z	N _O	Yes	
	21/10/2015			7/02/2016 1
	21/03/2016			0/05/2016 11
	21/06/2016			5/07/2016 18
	20/06/2016			8/08/2016 3
	21/10/2015 21/03/2016 21/06/2016 20/06/2016 24/06/2016 Sel	Ple Sel	S _e j.	17/02/2016 10/05/2016 15/07/2016 18/08/2016 30/08/2016 Sel

89624	89623	89622	89621	89620
89624 15/LO/0940 179018	89623 15/EM/0344	89622 14/SS/1043	89621 15/EE/0326	89620 15/LO/1419
179018	183906	142447	183975	
NHS	NHS Permission	NHS Permission	NHS Permission	NHS Permission
Victoria: GS-US- 312-0118 A phase 3 randomised open-label study evaluating the efficacy and safety of idelalisib in combination with obinutuzumab	MORAb-009-201 A randomised, double-blind, place-controlled study of the safety and efficacy of amatuximab in combination with pemetrexed and cisplatin in subjects with unresectable malignant pleural mesothelioma	UNIRAD: Randomized, doubled-blind, multicentre phase 111 trail evaluating the safety and benefit of adding everolimus to adjuvant hormone therapy in women with poor prognosis, ER+ and HER2 - primary breast cancer who remain free of disease after receiving	Seattle Genetics: SCRV35-023 A randomised, open label, phase 2 study of rituximab and bendamustine with or without brentuximab vedofin for relapsed or reflapsed or reflapsed or positive diffuse large B-cell lymphoma	PEARLS: A randomised, phase 3 frial with anti-PD 2 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy
13/11/2015	14/03/2016	06/03/2016	23/03/2016	21/03/2016
22/12/2015	23/03/2016	09/03/2016	04/04/2016	21/04/2016
No	Yes	No	No	N _o
39	19/07/2016 9	ω	12	31
	118			
	127			
			,	
N ₀	Z _O	Z	Z o	Z _o
P e	Se Ple	S Ple	S P e	So Po

http://ccfctp.nihr.ac.uk/Submission.aspx?MetaSubmissionld=41&Submissionld=4438&Trustld=1119

_	
#	
O	
0	
×	
-	
C.	
7	
9	
\supset	
=:	
=	
200	
.,	
굿	
75	
(J)	
\subseteq	
0	
=	
=.	
S	
S	
≃.	
\simeq	
-	
a	
S	
O	
×	
:≥	
~	
_	
Œ	
0	
īn	
~	
=	
\leq	
3	
70	
93	
97.	
0	
_	
=	
nld=4	
Į.	
4	
_	
So	
CD	
Č.	
ᅙ	
\preceq	
\supset	
70	
'n	
<u>~</u> .	
0	
_	
$\overline{}$	
T	
ĬI.	
+	
45	
ω	
ω	
No	
138&Tr	
Ξ.	
S	
=	
Q.	
11	
_	
ıstld=1119	
===	
9	

			m 1	m	ω Ι	
	89629	39628	39627	39626	9625	
	15/EM/0400	89628 14/LO/0100	89627 13/NW/0153 104669	89626 15/WS/0011 122822	89625 14/LO/1291	
	178129	135429			148513	
	NHS Permission	NHS Permission	NHS Permission	HRA Approval	NHS Permission	Permission
DOMPERIDONE JNJ-17296812: A multicenter, double-blind, randomised,	Phase 3, Randomised Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+Metastatic Breast Cancer Who Have Received Two Prior Anti-HER2 therapies and Require Systemic Treatment	APIPPRA - Arthritis Prevention In the Pre-clinical Phase of RA with Abatacept	CIPHER: Phase 11 multicentre study assessing the efficacy of Cabazitaxel in patients with HER2-negative metastatic breast cancer and having un-resectable brain metastasses.	BALLAD: A trial to evaluate the potential benefit of adjuvant chemotherapy for small bowel adenocarcinoma	PALLET - A phase 11 randomised study evaluating the biological and clinical effects of the combination of palociclib with letrozole as neo adjuvant therapy in post-menopausal women with ER+primary breast cancer.	compared to chlorambucil in combination with obinutuzumab for previously untreated chronic lymohocytic leukem
	16/02/2016	02/11/2015	16/02/2016		16/09/2015	
	25/02/2016	04/11/2015	23/02/2016		20/10/2015	
	N _o	Yes	No	N _o	Yes	
		31/12/2015 2	7		05/05/2016	
	Ф		7		34	
		57			198	
		59		12	232	
				10		
	Z	Yes	N _O	Z ₀	No	,
				05/		
				03/2015 27/		
				05/2016 29/0		
,				05/03/2015 27/05/2016 29/04/2016 08/06/2016 08/06/2016		
-				16/2016 08/0		
	Sel.	Ple Sel	Pie Sel	06/2016 Ple	S P le	Se

_	
-	
=	
O	
٠.	
-	
C	
Ö	
$\overline{}$	
⇁	
0	
-	
_	
=	
_	
$\overline{}$	
•	
$\boldsymbol{\omega}$	
0	
=	
\sim	
-	
תח	
۷,	
_	
О	
=	
ihr.ac.uk/Submission	
=	
m.	
97	
S	
— .	
0	
\simeq	
_	
-	
an a	
CO	
O	
×	
·~	
_	
\geq	
A	
V.	
22	
m.	
m	
۷,	
$\overline{\alpha}$	
\simeq	
~	
_	
≓.	
S.	
iss	
issi	
nissic	
nission	
nission	
nissionk	
nissionld	
nissionId=	
nissionId=	
າissionId=4	
າissionId=41	
າissionId=41	
າissionId=41&	
າissionId=41&ິ	
າissionId=41&S	
າissionId=41&Sບ	
າissionId=41&Sut	
nissionId=41&Subr	
on.aspx?MetaSubmissionId=41&Subm	
nissionId=41&Subm	
nissionId=41&Submi	
າissionId=41&Submis	
າissionId=41&Submiss	
nissionId=41&Submissi	
nissionId=41&Submissio	
าissionId=41&Submissior	
nissionId=41&Submission	
nissionId=41&SubmissionId	
าissionId=41&SubmissionId	
าissionId=41&SubmissionId=	
nissionId=41&SubmissionId=	
nissionId=41&SubmissionId=4	
nissionId=41&SubmissionId=44	
nissionId=41&SubmissionId=443	
nissionId=41&SubmissionId=443	
าissionId=41&SubmissionId=4438	
nissionId=41&SubmissionId=44388	
nissionId=41&SubmissionId=4438&	
nissionId=41&SubmissionId=4438&T	
nissionId=41&SubmissionId=4438&Tr	
nissionId=41&SubmissionId=4438&Tru	
nissionId=41&SubmissionId=4438&Tru	
nissionId=41&SubmissionId=4438&Trus	
nissionId=41&SubmissionId=4438&Trust	
nissionId=41&SubmissionId=4438&Trustl	
nissionId=41&SubmissionId=4438&TrustId	
nissionId=41&SubmissionId=4438&TrustId=	
nissionId=41&SubmissionId=4438&TrustId=	
nissionId=41&SubmissionId=4438&TrustId=1	
nissionId=41&SubmissionId=4438&TrustId=11	
nissionId=41&SubmissionId=4438&TrustId=111	
nissionId=41&SubmissionId=4438&TrustId=1119	
nissionId=41&SubmissionId=4438&TrustId=1119	
missionld	

http://	88	88	88		2/5/2018
89635 14/	634 13	9633 12	9632 16	9631 16	
14/WS/1120 1	89634 13/LO/1096 8	89633 12WA/0374 !	89632 16/LO/0075	89631 16/LO/0092	16/YH/0154
89635 14/WS/1120 161050 P	89630	98726	191435	194133	202759
HS ermission	NHS Permission	NHS Permission	HRA Approval	NHS Permission	HRA Approval
Registry: -up in xaban s in the	ii & 5, 8i a	HART Hughes Abdominal Repair Trial - Abdominal wall closure techniques to reduce incidence of incisional hemias	A prospective, multicentre, randomised trial: The effect of catheter valve Vs. standard catheter removal in outpatient settings on the patient discharge timings	GO29834 - Hamony: A phase Ib/II study evaluating the safety and efficacy of Obinutuzumab in combination with Polatuzamab vedotin and lenalidomide in patients with relapsed or refractory follicular or diffucse large B-cell lumphoma.	Placebo-controlled, parallel-group, Prospective Study to Evaluate the Safety and Efficiency of Domperidone in 6 month old to 12 year old Pediatric Subjects with Nausea and Vomiting due to
23/10/2015	21/10/2015	18/02/2016		21/03/2016	
27/10/2015	26/10/2015	23/02/2016		21/09/2016	
Yes	Yes	Yes	Z o	N _o	Z o
25/01/2016 4	11/02/2016 5	01/05/2016 5			CTP Submission Platform - Submission (Version 1.0.3)
				184	nission Pla
90	108	68			tform - Sut
94	113	73			omission (
			8		Version 1.0
					<u> </u>
	Z	Z	7	7	
	٥	ō	8	8	8
			23/03/2016		26/11/2015
			31/05/2016		07/04/2016
			23/03/2016 31/05/2016 07/07/2016 21/07/2016 19/08/2016 Sel		26/11/2015 07/04/2016 26/08/2016 29/06/2016 01/09/2016 Sei
			21/07/2016		29/06/2016
ω TI	(0.7)	(0.7)	19/08/2016		01/09/2016
Se e	Se.	Ple Sel	9 ⁶	S P e	Sel.

setting of thromboembolism

89636 14/NE/1176 16188 NHS Permission use of a prognostic tool (EndoPredict) to inform adjuvant chemotherapy decisions in low to medium risk arthroscopic capsualr release for patients referred to secondary care wit qualitaive study comparing early structured physiotherapy UK Frost- Multi-center randomised controlled trial with manipulation under anaesthesia vs evaluation nested EndoPredict: The verses Economic 02/08/2016 | 06/09/2016 | No 35 Within 70 Days

Ple. Sel.

Showing records 1 to 25 of 27. Pages: 1 2 Next >

89637 15/SC/0090 171171

NHS Permission

24/12/2015 |15/01/2016 |Yes

04/05/2016 22

110

132

No

Ple. Sel

Oestrogen
Receptor Positive,
Her-2 Negative
Early Breast
cancer: Feasibility,
Acceptability and
Economic impact
in Multicentre UK
NHS P

< Back

Copyright (c) Extros Limited 2013. All Rights Reserved. Web site developed in the City of Leeds, England by Extros Limited the bespoke software specialists.

⊕exbos

http://ccfctp.nihr.ac.uk/Submission.aspx?MetaSubmissionId=41&SubmissionId=4438&TrustId=1119